



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,310	12/17/2004	Hidehito Kotani	262507US0PCT	6711

22850 7590 03/23/2007
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA, VA 22314

EXAMINER

SHAW, AMANDA MARIE

ART UNIT	PAPER NUMBER
----------	--------------

1634

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

03/23/2007

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Interview Summary	Application No. 10/517,310	Applicant(s) KOTANI ET AL.	
	Examiner Amanda M. Shaw	Art Unit 1634	

All participants (applicant, applicant's representative, PTO personnel):

(1) Amanda M. Shaw.

(3) Thomas Cunningham.

(2) Diana Johannsen.

(4) _____.

Date of Interview: 09 March 2007.

Type: a) ☐ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: 1 and 2.

Identification of prior art discussed: The Imai et al reference (Molecular Cancer Therapeutics June 1, 2002) was discussed.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.


Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The Applicants wished to discuss the restriction requirement and the possibility of having the SNPs at positions 34 and 376 of the ABCG2 gene also examined if the SNP at position 421 of the ABCG2 gene was found allowable. The office made suggestions to the Applicants for amending the claims. As per request of the Applicants an alignment between SEQ ID NO 1 and AF103796 (cited in the Imai et al reference) is provided (see attachment).

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.


DIANA JOHANNSEN
PRIMARY EXAMINER

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent and Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy


If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.



Structure

Match: 1 Mismatch: -2 gap open: 5 gap extension: 2
x_dropoff: 50 expect: 10.000 wordsize: 11 Filter ☒ View option Standard
Masking character option X for protein, n for nucleotide Masking color option Black
☐ Show CDS translation Align

Sequence 2: gi|4185795|gb|AF103796.1|AF103796
Length = 2719 (1 .. 2719)



NOTE: If protein translation is reversed, please repeat the search with reverse strand of the query sequence.



Query- Seq id | 10/517310
 Sbjct - AF103796 Imai
 reference.

Query	1	ATGTCTTCCAGTAATGTGCGAAGTTTTTTATCCAGTGTACAAGGAAACACCAATGGCTTC	60
Sbjct	205	ATGTCTTCCAGTAATGTGCGAAGTTTTTTATCCAGTGTACAAGGAAACACCAATGGCTTC	264
Query	61	CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTTCAT	120
Sbjct	265	CCCGCGACAGTTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTTCAT	324
Query	121	AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACAGTTGAG	180
Sbjct	325	AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACAGTTGAG	384
Query	181	AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA	240
Sbjct	385	AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA	444
Query	241	CCCACAGGTGGAGGCCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT	300
Sbjct	445	CCCACAGGTGGAGGCCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT	504

Query	301	GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT	360
Sbjct	505	GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT	564
Query	361	TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACCTTA	420
Sbjct	565	TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACCTTA	624
Query	421	CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACATGACGAATCATGnnnnnnnnCGAACGG	480
Sbjct	625	CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACATGACGAATCATGAAAAAACGAACGG	684
Query	481	ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAAC	540
Sbjct	685	ATTAACAGGGTCATTGAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAAC	744
Query	541	CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT	600
Sbjct	745	CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT	804
Query	601	ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACCTGGCTTAGACTCAAGCACA	660
Sbjct	805	ATCACTGATCCTTCCATCTTGTCCTTGGATGAGCCTACAACCTGGCTTAGACTCAAGCACA	864
Query	661	GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC	720
Sbjct	865	GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC	924
Query	721	TCCATTATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC	780
Sbjct	925	TCCATTATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC	984
Query	781	TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT	840
Sbjct	985	TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT	1044
Query	841	GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAAATGGA	900
Sbjct	1045	GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAAATGGA	1104
Query	901	GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG	960
Sbjct	1105	GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG	1164
Query	961	CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC	1020
Sbjct	1165	CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC	1224
Query	1021	TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG	1080
Sbjct	1225	TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG	1284
Query	1081	ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCTCATCAACTCAGATGGGTT	1140
Sbjct	1285	ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCTCATCAACTCAGATGGGTT	1344
Query	1141	TCCAAGCGTTTCAATTCAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT	1200
Sbjct	1345	TCCAAGCGTTTCAATTCAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT	1404
Query	1201	GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT	1260
Sbjct	1405	GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT	1464
Query	1261	ACTGGAATCCAGAACAGAGCTGGGGTTCTTCTTCTCCTGACGACCAACCAGTGTTTCAGC	1320

```

Sbjct 1465 ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTCAGC 1524
Query 1321 AGTGTTCAGCCGTGGAACCTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC 1380
|||||
Sbjct 1525 AGTGTTCAGCCGTGGAACCTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC 1584
Query 1381 AGCGGATACTACAGAGTGTCTATTTTCCTTGGAAGTGTATCTGATTTATTACCC 1440
|||||
Sbjct 1585 AGCGGATACTACAGAGTGTCTATTTTCCTTGGAAGTGTATCTGATTTATTACCC 1644
Query 1441 ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG 1500
|||||
Sbjct 1645 ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG 1704
Query 1501 CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTTCAGCC 1560
|||||
Sbjct 1705 CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTTCAGCC 1764
Query 1561 AGTTCCATGGCACTGGCCATAGCAGCAGGTGAGAGTGTGGTTTCTGTAGCAACACTTCTC 1620
|||||
Sbjct 1765 AGTTCCATGGCACTGGCCATAGCAGCAGGTGAGAGTGTGGTTTCTGTAGCAACACTTCTC 1824
Query 1621 ATGACCATCTGTTTTGTGTTTATGATGATTTTTTCAGGTCTGTTGGTCAATCTCACAACC 1680
|||||
Sbjct 1825 ATGACCATCTGTTTTGTGTTTATGATGATTTTTTCAGGTCTGTTGGTCAATCTCACAACC 1884
Query 1681 ATTGCATCTTGGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCT 1740
|||||
Sbjct 1885 ATTGCATCTTGGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCT 1944
Query 1741 TTGCAGCATAATGAATTTTTTGGGACAAAACCTTCTGCCCAGGACTCAATGCAACAGGAAAC 1800
|||||
Sbjct 1945 TTGCAGCATAATGAATTTTTTGGGACAAAACCTTCTGCCCAGGACTCAATGCAACAGGAAAC 2004
Query 1801 AATCCTTGTAACATGCAACATGTACTGGCGAAGAATATTTGGTAAAGCAGGGCATCGAT 1860
|||||
Sbjct 2005 AATCCTTGTAACATGCAACATGTACTGGCGAAGAATATTTGGTAAAGCAGGGCATCGAT 2064
Query 1861 CTCTCACCTGGGGCTTGTGGAAGAATCACGTGGCCTTGGCTTGTATGATTGTTATTTTC 1920
|||||
Sbjct 2065 CTCTCACCTGGGGCTTGTGGAAGAATCACGTGGCCTTGGCTTGTATGATTGTTATTTTC 2124
Query 1921 CTCACAATTGCCTACCTGAAATTGTTATTTCTTAAAAAATATTCTTAA 1968
|||||
Sbjct 2125 CTCACAATTGCCTACCTGAAATTGTTATTTCTTAAAAAATATTCTTAA 2172

```

CPU time: 0.02 user secs. 0.01 sys. secs 0.03 total secs.

Lambda K H
1.33 0.621 1.12

Gapped
Lambda K H
1.33 0.621 1.12

Matrix: blastn matrix:1 -2
Gap Penalties: Existence: 5, Extension: 2
Number of Sequences: 1
Number of Hits to DB: 557
Number of extensions: 7
Number of successful extensions: 1
Number of sequences better than 10.0: 1
Number of HSP's gapped: 1
Number of HSP's successfully gapped: 1

Length of query: 1968
Length of database: 19,997,918,785
Length adjustment: 27
Effective length of query: 1941
Effective length of database: 19,997,918,758
Effective search space: 38815960309278
Effective search space used: 38815960309278
X1: 11 (21.1 bits)
X2: 26 (50.0 bits)
X3: 26 (50.0 bits)
S1: 14 (27.6 bits)
S2: 22 (43.0 bits)